ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Dacomitinib (PF-00299804)
Drug: Active Comparator (erlotinib)
Drug: Placebo erlotinib
Drug: Placebo PF00299804

Registration Number: NCT01360554

Lead Sponsor: Pfizer

Brief Summary: This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 878

Inclusion Criteria

Evidence of pathologically confirmed, advanced NSCLC (with known histology).
Prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced NSCLC).
Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.
Adequate renal, hematologic, liver function.
ECOG PS of 0-2.
Radiologically measurable disease.

Exclusion Criteria

Small cell histology.
Symptomatic brain mets or known leptomeningeal mets.
Prior therapy with agent known or proposed to be active by action on EGFR tyrosine kinase or other HER family proteins.
Uncontrolled medical disorders.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A	Dacomitinib (PF-00299804)	Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
A	Placebo erlotinib	Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
B	Active Comparator (erlotinib)	Blinded active comparator (erlotinib) + blinded placebo PF-00299804
B	Placebo PF00299804	Blinded active comparator (erlotinib) + blinded placebo PF-00299804

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS) Per Independent Radiologic Review.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	PFS was defined as the time from randomization to the date of disease progression as by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.
Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Independent Radiologic Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.

Secondary Outcome Measures

Name	Time	Method
PFS Based on Investigator Review in KRAS-WT Participants.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions. Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.
Overall Survival (OS).	From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months.	OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up).
Best Overall Response (BOR) Per Independent Radiologic Review.	From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	The BOR was the best response per RECIST (version 1.1) criteria as assessed by independent assessment recorded from randomization until disease progression. Per RECIST version 1.1: Complete Response (CR): disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\<10 mm) and no appearance of new unequivocal malignant lesions; Partial Response (PR): \>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; Progressive Disease (PD): \>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.
Trough Concentrations (Ctrough) of Dacomitinib.	Baseline up to Cycle 5 Day 1	Mean Ctrough values of dacomitinib observed from Cycle 2 through 5, Day 1 for dose compliant participants.
OS in KRAS-WT Participants.	From date of randomization until the date of death from any cause or last date known to be alive, participants were followed up regardless of the reason for discontinuation from study treatment at intervals of no longer than every 2 months.	OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive (ie, at their last known alive date from long term follow-up). Tumor tissue from participants' original diagnostic biopsies or recently obtained biopsies were analyzed to determine KRAS status.
Mean and Difference in Mean in Lung Cancer Symptom Scores as Assessed by the EORTC QLQ- LC13.	Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.	The QLQ-LC13 included questions specific to the disease associated symptoms (dyspnea, cough, haemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy, and alopecia), and analgesic use of lung cancer patients. Scores range from 0-100 and a higher score indicates greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.
PFS Based on Investigator Review.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	PFS was defined as the time from randomization to the date of disease progression as by RECIST v1.1 per Investigator's Review or death due to any cause, whichever occurred first. Objective progression was defined as a 20% increase in the sum of the diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions, or the appearance of any new unequivocal malignant lesions.
Duration of Response (DR) Based on Independent Radiologic Review.	From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	DR was defined as the time from first documentation of response assessed by independent review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.
Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough Patient Reported Disease Symptoms.	Data taken from Cycle 1 day 1 to the end of treatment or withdrawal.	TTD defined as the time from first dose (baseline) to the first time a patient's score in pain, dyspnea, fatigue or cough from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-LC13) increased by ≥10 points. A ≥10 point increase in score had to be maintained for ≥2 consecutive cycles for the symptom to be considered deteriorated. Participants were censored at the last time when they completed an assessment for pain, dyspnea, fatigue or cough if they had not deteriorated. A 10 point or higher change in the score is perceived by participants as clinically significant.
DR Based on Investigator Review.	From date of randomization until progression or death due to any cause. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	DR was defined as the time from first documentation of response assessed by investigator review (CR or PR whichever occurred first) to date of progression or death due to any cause, whichever occurs first. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.
Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)	Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.	EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a better level of quality of life. Overall scores present the mean score for that scale from all time-point data.
Mean and Difference in Mean in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30.	Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.	EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Scores ranged from 0-100 where a higher score indicated a greater degree of symptoms/problems. Overall scores present the mean score for that scale from all time-point data.
BOR Per Investigator Review.	From date of randomization until progression or initiation of new anti-cancer therapy or death. Participants were followed up until progressive disease regardless of start of subsequent cancer therapy.	The BOR was the best response per RECIST (version 1.1) criteria as assessed by investigator assessment recorded from randomization until disease progression. Per RECIST version 1.1: CR: disappearance of all pre-existing lesions except nodal disease, with all nodal lesions decreased to normal size (short axis\<10 mm) and no appearance of new unequivocal malignant lesions; PR: \>=30% decrease from baseline sum of diameters of all target lesions with no unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions; PD: \>=20% increase in the sum of diameters of target lesions above the smallest sum observed, with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions or appearance of any new unequivocal malignant lesions.
Trough Concentrations (Ctrough) of PF-05199265.	Baseline up to Cycle 5 Day 1	Mean Ctrough values of PF-05199265 observed from Cycle 2 through 5, Day 1 for dose compliant participants.
Mean and Difference in Mean of the EuroQoL-5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Score	Data taken from Cycle 1 day 1 to the end of treatment or withdrawal, averaged (mean) to provide overall scores.	The EQ-5D is a validated and reliable self-report preference-based measure developed by the EuroQoL Group to assess health-related quality of life. It consists of the EQ-5D descriptive system and a visual analogue scale-the EQ VAS. The EQ-5D descriptive system measures a participants' health state on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels, reflecting "no health problems," "moderate health problems," and "extreme health problems." The EQ VAS records the respondent's self-rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).

Trial Locations

Locations (209): Westwood Bowyer Clinic, Peter Morton Medical Building
🇺🇸
Los Angeles, California, United States
Winship Cancer Institute of Emory University
🇺🇸
Atlanta, Georgia, United States
Emory Clinic
🇺🇸
Atlanta, Georgia, United States
North Mississippi Hematology and Oncology Associates, Ltd.,
🇺🇸
Tupelo, Mississippi, United States
Drug Managerrent Only:
🇺🇸
Los Angeles, California, United States
Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center
🇺🇸
Los Angeles, California, United States
TORI Central Administration
🇺🇸
Los Angeles, California, United States
Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU)
🇺🇸
Los Angeles, California, United States
Regulatory Management:
🇺🇸
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸
Los Angeles, California, United States
CHU de Poitiers
🇫🇷
Poitiers Cedex, France
Kantonsspital St. Gallen
🇨🇭
St. Gallen, Switzerland
Mercy clinic oklahoma communities, Inc. - Mercy clinic oncology/Hematology - Norman
🇺🇸
Norman, Oklahoma, United States
University of Washington Medical Center
🇺🇸
Seattle, Washington, United States
KPE/Onkologikliniken
🇸🇪
Karlstad, Sweden
HOSPITAL DE LA SANTA CREU I SANT PAU - Pharmacy
🇪🇸
Barcelona, Spain
Kent Oncology Centre
🇬🇧
Maidstone, Kent, United Kingdom
Mercy Physicians of Oklahoma-Communities, Inc. - Mercy Clinic Oncology/Hematology - McAuley
🇺🇸
Oklahoma City, Oklahoma, United States
University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Pandy Kalman Megyei Korhaz, Aktiv Tudogyogyaszat
🇭🇺
Gyula, Hungary
Highlands Oncology Group, PA
🇺🇸
Rogers, Arkansas, United States
North Mississippi Hematology and Oncology Associates, Ltd.
🇺🇸
Starkville, Mississippi, United States
Norwalk Hospital
🇺🇸
Norwalk, Connecticut, United States
Highlands Oncology Group PA
🇺🇸
Fayetteville, Arkansas, United States
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
🇺🇸
Mesa, Arizona, United States
Desert Oncology Associates dba Ironwood Cancer and Research Centers
🇺🇸
Mesa, Arizona, United States
Emory University Hospital
🇺🇸
Atlanta, Georgia, United States
Kyushu University Hospital Respiratory Medicine
🇯🇵
Fukuoka, Japan
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱
Otwock, Mazowieckie, Poland
Oncology Center # 2
🇷🇺
Sochi, Krasnodarskij Kraj, Russian Federation
Ironwood physicians P C dba Ironwood Cancer & Research Centers
🇺🇸
Chandler, Arizona, United States
Okayama University Hospital
🇯🇵
Okayama-city, Okayama, Japan
Zoz All-Medi
🇵🇱
Otwock, Mazowieckie, Poland
Samara Regional Clinical Oncology Dispensary
🇷🇺
Samara, Russian Federation
National Hospital Organization Shikoku Cancer Center
🇯🇵
Matsuyama-city, Ehime, Japan
Shizuoka Cancer Center
🇯🇵
Sunto-gun, Shizuoka, Japan
Fakultna nemocnica s poliklinikou
🇸🇰
Nove Zamky, Slovakia
Grand Hopital de Charleroi Oncologie-Hematologie
🇧🇪
Charleroi, Belgium
Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie
🇵🇱
Warsaw, Mazowieckie, Poland
Clinic of Hospital Surgery
🇷🇺
Saint-Petersburg, Russian Federation
National Hp. Org. Kyushu Medical Center
🇯🇵
Fukuoka, Japan
National Hospital Organization Kyushu Cancer Center/Department of Thoracic Oncology
🇯🇵
Fukuoka, Japan
Oaxaca Site Management Organization
🇲🇽
Oaxaca, Mexico
Nukleomed
🇵🇱
Warsaw, Mazowieckie, Poland
Federal State Healthcare Clinical Hospital #101 of the Federal Biomedical Agency
🇷🇺
Pyatigorsk, Stavropolskij Kraj, Russian Federation
Pyatigorsk Oncology Center
🇷🇺
Pyatigorsk, Russian Federation
St.-Petersburg State Medical University I.P.Pavlov of Roszdrav
🇷🇺
Saint-Petersburg, Russian Federation
Univerzitna Nemocnica Bratislava, Klinika pneumologie a ftizeologie I- Oddelenie klinickej onkologie
🇸🇰
Bratislava, Slovakia
Specializovana nemocnica sv. Svorada Zobor, n.o.
🇸🇰
Nitra, Slovakia
GVI Oncology Clinical Research Unit
🇿🇦
Kraaifontein, Western Cape, South Africa
Hospital General Universitario de Elche - Edificio UIAE
🇪🇸
Elche, Alicante, Spain
Northwest Alabama Cancer Center
🇺🇸
Muscle Shoals, Alabama, United States
University of South Alabama Mitchell Cancer Institute
🇺🇸
Mobile, Alabama, United States
Central Hematology Oncology Medical Group Inc.
🇺🇸
Alhambra, California, United States
City of Hope
🇺🇸
Duarte, California, United States
Drug Management Only
🇺🇸
Los Angeles, California, United States
UCLA West Medical Pharmacy
🇺🇸
Los Angeles, California, United States
St. Jude Heritage Healthcare
🇺🇸
Fullerton, California, United States
Regulatory Management Only:
🇺🇸
Los Angeles, California, United States
UCLA/Pasadena Healthcare Hematology-Oncology
🇺🇸
Pasadena, California, United States
Central Hematology Oncology Medical Group, Inc.
🇺🇸
Pasadena, California, United States
Central Coast Medical Oncology Corporation
🇺🇸
Santa Maria, California, United States
Cancer Care Associates Medical Group Inc.
🇺🇸
Redondo Beach, California, United States
UCLA Santa Monica Medical Center & Orthopedic Hospital
🇺🇸
Santa Monica, California, United States
City of Hope South Pasadena Cancer Center
🇺🇸
South Pasadena, California, United States
UCLA/Santa Clarita Valley Cancer Center
🇺🇸
Valencia, California, United States
UCLA Cancer Center
🇺🇸
Westlake Village, California, United States
Florida Hospital
🇺🇸
Orlando, Florida, United States
Cancer Institute of Florida
🇺🇸
Orlando, Florida, United States
Hematology and Oncology Consultants, P.A.
🇺🇸
Orlando, Florida, United States
Hematology Oncology Associates of the Treasure Coast
🇺🇸
Port Saint Lucie, Florida, United States
Emory University Hospital Midtown
🇺🇸
Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, PC
🇺🇸
Cartersville, Georgia, United States
John B. Amos Cancer Center
🇺🇸
Columbus, Georgia, United States
Northwest Georgia Oncology Centers, P.C.
🇺🇸
Marietta, Georgia, United States
The Cancer Center at DeKalb Medical
🇺🇸
Decatur, Georgia, United States
Suburban Hematology-Oncology Associates, P.C.
🇺🇸
Snellville, Georgia, United States
Northeast Georgia Medical Center
🇺🇸
Gainesville, Georgia, United States
Oncology Specialists of North Georgia, LLC
🇺🇸
Gainesville, Georgia, United States
Illinois Cancer Specialists
🇺🇸
Niles, Illinois, United States
Ingalls Memorial Hospital - In-Patient Pharmacy
🇺🇸
Harvey, Illinois, United States
The Longstreet Clinic Cancer Center
🇺🇸
Gainesville, Georgia, United States
Monroe Medical Associates
🇺🇸
Munster, Indiana, United States
Cedar Valley Medical Specialists, P.C.
🇺🇸
Waterloo, Iowa, United States
Deaconess Clinic Downtown
🇺🇸
Evansville, Indiana, United States
Kentucky Cancer Clinic
🇺🇸
Hazard, Kentucky, United States
University Medical Center, Inc.
🇺🇸
Louisville, Kentucky, United States
Baptist Hospital East
🇺🇸
Louisville, Kentucky, United States
University Medical Center, Inc
🇺🇸
Louisville, Kentucky, United States
Siteman Cancer Center-West County
🇺🇸
Creve Coeur, Missouri, United States
Barnes Jewish Hospital
🇺🇸
Saint Louis, Missouri, United States
Washington University School of Medicine-IDS Pharmacy
🇺🇸
Saint Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center /Mary Hitchcock Memorial Hospital
🇺🇸
Lebanon, New Hampshire, United States
Siteman Cancer Center-St. Peters
🇺🇸
Saint Peters, Missouri, United States
Oncology and Hematology Specialists, P.A.
🇺🇸
Denville, New Jersey, United States
Carolina Oncology Specialists PA
🇺🇸
Lenoir, North Carolina, United States
Good Samaritan Hospital Samaritan Ambulatory Infusion Services
🇺🇸
Corvallis, Oregon, United States
Mercy Hospital Oklahoma City - Oncology Infusion
🇺🇸
Oklahoma City, Oklahoma, United States
Samaritan Hematology & Oncology Consultants
🇺🇸
Corvallis, Oregon, United States
Samaritan Pharmacy Services
🇺🇸
Corvallis, Oregon, United States
Samaritan North Lincoln Hospital
🇺🇸
Lincoln City, Oregon, United States
Robert Packer Hospital
🇺🇸
Sayre, Pennsylvania, United States
Samaritan Pacific Communities Hospital
🇺🇸
Newport, Oregon, United States
Guthrie Clinic, Limited
🇺🇸
Sayre, Pennsylvania, United States
Hôpital Paris Saint Joseph
🇫🇷
Paris, France
Kadlec Clinic Hematology and Oncology
🇺🇸
Kennewick, Washington, United States
Outpatient Imaging Center
🇺🇸
Richland, Washington, United States
Texas Oncology - Waco
🇺🇸
Waco, Texas, United States
Texas Oncology-Longview Cancer Center
🇺🇸
Longview, Texas, United States
Texas Oncology-Tyler
🇺🇸
Tyler, Texas, United States
Kadlec Medical Center
🇺🇸
Richland, Washington, United States
Seattle Cancer Care Alliance
🇺🇸
Seattle, Washington, United States
Sozialmedizinisches Zentrum Baumgartner Hoehe - Otto Wagner Spital und Pflegezentrum
🇦🇹
Vienna, Austria
Institut Jules Bordet
🇧🇪
Brussels, Belgium
Laboratoire de la Porte de Hall
🇧🇪
Brussels, Belgium
Heilig Hart Ziekenhuis Roeselare-Menen
🇧🇪
Roeselare, Belgium
CHU Ambroise Parre- Service Biologie Clinique
🇧🇪
Mons, Belgium
Tumour Hospital of Guangxi Zhuang Autonomous Region
🇨🇳
Nanning, Guangxi, China
Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center
🇨🇳
Wuhan, Hubei, China
Jilin Provincial Cancer Hospital
🇨🇳
Changchun, Jilin, China
West China Hospital of Sichuan University
🇨🇳
Chengdu, Sichuan, China
Aalborg Sygehus Syd
🇩🇰
Aalborg, Denmark
Shanghai Pulmonary Hospital
🇨🇳
Shanghai, China
Satakunnan keskussairaala/Keuhkosairauksien osasto A4
🇫🇮
Pori, Finland
Centre Georges Francois Leclerc
🇫🇷
Dijon, France
Helsingin yliopistollinen sairaala, Meilahden kolmiosairaala, keuhkosairauksien poliklinikka
🇫🇮
Helsinki, Finland
Hopital Albert Michallon
🇫🇷
Grenoble cedex 09, France
Institut de Cancerologie de lOuest - Rene Gauducheau
🇫🇷
Saint Herblain cedex, France
Lungenfachklinik Immenhausen
🇩🇪
Immenhausen, Germany
Universitaetsklinikum Aachen
🇩🇪
Aachen, Germany
University Hospital of Larissa
🇬🇷
Larissa, Thessaly, Greece
Krankenhaus Bethanien, Medizinische Klinik III
🇩🇪
Moers, Germany
Asklepios Fachkliniken Muenchen-Gauting
🇩🇪
Gauting, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet
🇩🇪
Mainz, Germany
Sotiria General Hospital of Athens
🇬🇷
Athens, Greece
University Hospital of Heraklion
🇬🇷
Heraklion, Greece
Semmelweis Egyetem Pulmonologiai Klinika
🇭🇺
Budapest, Hungary
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
🇭🇺
Debrecen, Hungary
Veszprem Megyei Onkormanyzat Tudogyogyintezete
🇭🇺
Farkasgyepu, Hungary
Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft.
🇭🇺
Nyiregyhaza, Hungary
Zala Megyei Korhaz, Pulmonologiai Osztaly
🇭🇺
Zalaegerszeg-Pozva, Hungary
Vedanta Institute of Medical Sciences
🇮🇳
Ahmedabad, Gujarat, India
Manipal Hospital
🇮🇳
Bangalore, Karnataka, India
Tata Memorial Centre
🇮🇳
Mumbai, Maharashtra, India
Beaumont Hospital
🇮🇪
Dublin, Leinster, Ireland
St. James Hospital
🇮🇪
Dublin, Ireland
St Vincent's University Hospital
🇮🇪
Dublin, Leinster, Ireland
Aichi cancer center central hospital /Thoracic Oncology
🇯🇵
Nagoya, Aichi, Japan
National Cancer Center Hospital East
🇯🇵
Kashiwa, Chiba, Japan
National Hospital Organization Asahikawa Medical Center
🇯🇵
Asahikawa, Hokkaido, Japan
Hyogo Cancer Center
🇯🇵
Akashi, Hyogo, Japan
Kanagawa Cardiovascular and Respiratory Center
🇯🇵
Yokohama, Kanagawa, Japan
Kurashiki Central Hospital
🇯🇵
Kurashiki, Okayama, Japan
Kanazawa University Hospital
🇯🇵
Kanazawa city, Ishikawa, Japan
Tohoku University Hospital
🇯🇵
Sendai, Miyagi, Japan
National Hospital Organization Kinki-chuo Chest Medical Center
🇯🇵
Sakai-Shi, Osaka-fu, Japan
Osaka City General Hospital Department of Clinical Oncology
🇯🇵
Osaka-city, Osaka, Japan
Kinki University Hospital
🇯🇵
Osakasayama-shi, Osaka, Japan
National Cancer Center Hospital
🇯🇵
Chuo-Ku, Tokyo, Japan
National Hospital Organization, Yamaguchi-Ube Medical Center
🇯🇵
Ube-shi, Yamaguchi, Japan
The Cancer Institute Hospital of JFCR
🇯🇵
Koto-ku, Tokyo, Japan
City Hospital #2 Krasnodar Multi-Field Diagnostic and Treatment Association
🇷🇺
Krasnodar, Krasnodarskij Kraj, Russian Federation
Hospital Universitario 12 de Octubre-Radiology
🇪🇸
Madrid, Spain
City Clinical Oncology Dispensary
🇷🇺
Saint-Petersburg, Russian Federation
Military Medical Academy n.a. S.M.Kirov
🇷🇺
Saint-Petersburg, Russian Federation
Research Institute of Pulmonology
🇷🇺
Saint-Petersburg, Russian Federation
Russian Scientific Center of Radiology and Surgical Technologies
🇷🇺
Saint-Petersburg, Russian Federation
WCR: Wits Clinical Research
🇿🇦
Parktown,Johannesburg, Gauteng, South Africa
Hospital Universitari Germans Trias i Pujol
🇪🇸
Badalona, Barcelona, Spain
Department of Oncotherapy
🇿🇦
Bloemfontein, South Africa
GVI Oncology
🇿🇦
Port Elizabeth, South Africa
Hospital Provincial de Castellon - Servicio de Oncologia
🇪🇸
Castellón, Castellon, Spain
Hospital de la Santa Creu i Sant Pau - Anatomia Patológica
🇪🇸
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau - AGDAC
🇪🇸
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau - Hospital de Día
🇪🇸
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau - Diagnostic per la Imatge i Med. Nuclear
🇪🇸
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸
Barcelona, Spain
Hospital Provincial de Castellon (Farmacia)
🇪🇸
Castellon, Spain
Hospital Universitario 12 de Octubre01
🇪🇸
Madrid, Spain
Hospital Universitario Madrid Sanchinarro
🇪🇸
Madrid, Spain
Kantonsspital Aarau
🇨🇭
Aarau, Switzerland
Karolinska Universitetssjukhuset
🇸🇪
Stockholm, Sweden
Hospital Universitario Virgen del Rocio. Hospital General Planta Baja. Servicio de Oncologia.
🇪🇸
Sevilla, Spain
Istituto Oncologico della Svizzera Italiana
🇨🇭
Bellinzona, Switzerland
Hopitaux Universitaires de Geneve
🇨🇭
Geneve 14, Switzerland
Ospedale Regionale di Locarno La Carita
🇨🇭
Locarno, Switzerland
Leicester Royal Infirmary
🇬🇧
Leicester, United Kingdom
New Cross Hospital - Royal Wolverhampton Hospital NHS Trust
🇬🇧
Wolverhampton, West Midlands, United Kingdom
Christie Hospital NHS Trust
🇬🇧
Manchester, United Kingdom
Cancer Clinical Trials Unit
🇬🇧
London, United Kingdom
North Middlesex NHS Trust
🇬🇧
Edmonton, United Kingdom
Christie Hospital NHS Trust, Department of Medical Oncology
🇬🇧
Manchester, United Kingdom
Lung and Melanoma Research Team
🇬🇧
Manchester, United Kingdom
University of South Alabama Medical Center
🇺🇸
Mobile, Alabama, United States
UCLA Hematology Oncology-Alhambra
🇺🇸
Alhambra, California, United States
UCLA Hematology Oncology-Parkside
🇺🇸
Santa Monica, California, United States
UCLA Hematology Oncology-Santa Monica
🇺🇸
Santa Monica, California, United States
Stony Brook University-Cancer Center
🇺🇸
Stony Brook, New York, United States
Oncology Department
🇮🇪
Waterford, Ireland
Atlanta Cancer Care
🇺🇸
Decatur, Georgia, United States
Georgia Cancer Specialists
🇺🇸
Decatur, Georgia, United States
Karmanos Cancer Institute at Farmington Hills
🇺🇸
Farmington Hills, Michigan, United States
Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Samsung Medical Center, Clinical Trial Center
🇰🇷
Seoul, Korea, Republic of
Asan Medical Center, Department of Oncology
🇰🇷
Seoul, Korea, Republic of
Investigational Drug Services, Florida Hospital
🇺🇸
Orlando, Florida, United States
Ingalls Memorial Hospital
🇺🇸
Harvey, Illinois, United States
Ruby Hall Clinic
🇮🇳
Pune, Maharastra, India